These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 14720633)

  • 21. Generic drugs: international trends and policy developments in Australia.
    Lofgren H
    Aust Health Rev; 2004; 27(1):39-48. PubMed ID: 15362295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with independent pharmacy owners' satisfaction with Medicare Part D contracts.
    Zhang S; Doucette WR; Urmie JM; Xie Y; Brooks JM
    Res Social Adm Pharm; 2010 Jun; 6(2):121-9. PubMed ID: 20511111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pricing of pharmaceuticals: an international comparison.
    Dickson M
    Clin Ther; 1992; 14(4):604-10; discussion 603. PubMed ID: 1525794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse pharmaceutical payment incentives and providers' behaviour: the emergence of GP-owned gateway pharmacies in Taiwan.
    Lee YC; Huang KH; Huang YT
    Health Policy Plan; 2007 Nov; 22(6):427-35. PubMed ID: 17901065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand.
    Danzon PM; Ketcham JD
    Front Health Policy Res; 2004; 7():1-54. PubMed ID: 15612334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaceutical pricing and reimbursement reforms in Greece.
    Yfantopoulos J
    Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.
    Andersson K; Petzold MG; Sonesson C; Lönnroth K; Carlsten A
    Health Policy; 2006 Dec; 79(2-3):231-43. PubMed ID: 16473436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of copayments and generic substitution on the use and costs of prescription drugs.
    Smith DG
    Inquiry; 1993; 30(2):189-98. PubMed ID: 8314607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios.
    Gress S; Niebuhr D; May U; Wasem J
    Pharmacoeconomics; 2007; 25(6):443-54. PubMed ID: 17523750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance.
    Godman B; Wettermark B; Hoffmann M; Andersson K; Haycox A; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):65-83. PubMed ID: 19371180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of generic reference pricing interventions in the statin market.
    Puig-Junoy J
    Health Policy; 2007 Nov; 84(1):14-29. PubMed ID: 17368619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
    McManus P; Birkett DJ; Dudley J; Stevens A
    Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug policy down under: Australia's pharmaceutical benefits scheme.
    Duckett SJ
    Health Care Financ Rev; 2004; 25(3):55-67. PubMed ID: 15229996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How removing prescription drugs from reimbursement lists increases the pharmaceutical expenditures for alternatives.
    Gür Ali O; Topaler B
    Eur J Health Econ; 2011 Dec; 12(6):553-62. PubMed ID: 20717700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managing psychotropic drug costs: will formularies work?
    Huskamp HA
    Health Aff (Millwood); 2003; 22(5):84-96. PubMed ID: 14515884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific region.
    Chen Y; Schweitzer SO
    Value Health; 2008 Mar; 11 Suppl 1():S124-9. PubMed ID: 18387056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The drug budget silo mentality: the French case.
    Le Pen C
    Value Health; 2003; 6 Suppl 1():S10-9. PubMed ID: 12846922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Managing prescription drug costs.
    Sica JM
    Empl Benefits J; 2001 Mar; 26(1):35-40. PubMed ID: 11272515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.